-
1
-
-
0141446228
-
Enhancing incretin action for the treatment of type 2 diabetes.
-
Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003; 26: 2929-2940.
-
(2003)
Diabetes Care
, vol.26
, pp. 2929-2940
-
-
Drucker, D.J.1
-
2
-
-
0035432607
-
Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment.
-
Larsen J, Hylleberg B, Ng K, Damsbo P. Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment. Diabetes Care 2001; 24: 1416-1421.
-
(2001)
Diabetes Care
, vol.24
, pp. 1416-1421
-
-
Larsen, J.1
Hylleberg, B.2
Ng, K.3
Damsbo, P.4
-
3
-
-
0043169338
-
Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans.
-
Quddusi S, Vahl TP, Hanson K, Prigeon RL, D'Alessio DA. Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans. Diabetes Care 2003; 26: 791-798.
-
(2003)
Diabetes Care
, vol.26
, pp. 791-798
-
-
Quddusi, S.1
Vahl, T.P.2
Hanson, K.3
Prigeon, R.L.4
D'Alessio, D.A.5
-
4
-
-
0032976939
-
Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.
-
Toft-Nielsen MB, Madsbad S, Holst JJ. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 1999; 22: 1137-1143.
-
(1999)
Diabetes Care
, vol.22
, pp. 1137-1143
-
-
Toft-Nielsen, M.B.1
Madsbad, S.2
Holst, J.J.3
-
5
-
-
0037045845
-
Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study.
-
Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002; 359: 824-830.
-
(2002)
Lancet
, vol.359
, pp. 824-830
-
-
Zander, M.1
Madsbad, S.2
Madsen, J.L.3
Holst, J.J.4
-
6
-
-
0345017698
-
Recombinant glucagon-like peptide-1 (7-36 amide) lowers fasting serum glucose in a broad spectrum of patients with type 2 diabetes.
-
Ehlers MR, Klaff LJ, D'Alessio DA et al. Recombinant glucagon-like peptide-1 (7-36 amide) lowers fasting serum glucose in a broad spectrum of patients with type 2 diabetes. Horm Metab Res 2003; 35: 611-616.
-
(2003)
Horm Metab Res
, vol.35
, pp. 611-616
-
-
Ehlers, M.R.1
Klaff, L.J.2
D'Alessio, D.A.3
-
7
-
-
0037850667
-
Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes.
-
Fineman MS, Bicsak TA, Shen LZ et al. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 2003; 26: 2370-2377.
-
(2003)
Diabetes Care
, vol.26
, pp. 2370-2377
-
-
Fineman, M.S.1
Bicsak, T.A.2
Shen, L.Z.3
-
8
-
-
2342599057
-
One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.
-
Degn KB, Juhl CB, Sturis J et al. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 2004; 53: 1187-1194.
-
(2004)
Diabetes
, vol.53
, pp. 1187-1194
-
-
Degn, K.B.1
Juhl, C.B.2
Sturis, J.3
-
9
-
-
4644300651
-
Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes.
-
Fineman MS, Shen LZ, Taylor K, Kim DD, Baron AD. Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes. Diabetes Metab Res Rev 2004; 20: 411-417.
-
(2004)
Diabetes Metab Res Rev
, vol.20
, pp. 411-417
-
-
Fineman, M.S.1
Shen, L.Z.2
Taylor, K.3
Kim, D.D.4
Baron, A.D.5
-
10
-
-
0027248866
-
Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.
-
Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993; 36: 741-744.
-
(1993)
Diabetologia
, vol.36
, pp. 741-744
-
-
Nauck, M.A.1
Kleine, N.2
Orskov, C.3
Holst, J.J.4
Willms, B.5
Creutzfeldt, W.6
|